Table 4.

Comparative assessment of hormonal and metabolic characteristics of PCOS patients before and after 3 months of MI and DHI (40:1) supplementation of PCOS patients with IR (group 1) and normoinsulinemic PCOS (group 2)

Characteristics	Group 1: PCOS with IR (n = 17)				Group 2: PCOS without IR (n = 17)				p 3
	before, M (SD)	after, M (SD)	differences (after-before)	p 1	before, M (SD)	after, M (SD)	differences (after-before)	p 2
	*Me (Q1; Q3)	*Me (Q1; Q3)	Me (Q1; Q3)		*Me (Q1; Q3)	*Me (Q1; Q3)	Me (Q1; Q3)
FSH, mIU/mL	5.20 (4.5; 6.3)	5.65 (5.0; 6.0)	0.6 (0.0; 1.0)	0.3255§	5.4 (4.5; 7.0)	5.0 (4.5; 6.8)	0 (−0.3; 0.4)	0.9628§	0.313/0.993§
LH, mIU/mL	7.09 (4.3; 8.9)	6.03 (5.0; 7.8)	−1 (2.6; 0.8)	0.1739§	5.8 (5.0; 9.3)	6.0 (4.8; 7.0)	−1 (−2.0; 0.0)	0.2426§	0.775/0.652§
Estradiol, pmol/L	140 (95.0; 316.0)	170 (128.0; 355.0)	20 (0.0;57.0)	0.0186*	148 (112.0; 249.0)	190 (160.0; 304.0)	29 (19.0; 55.0)	0.0057*	0.098/0.809*
Total testosterone, nmol/L	2.2 (1.8; 2.7)	170 (120.0; 355.0)	20 (0.0; 57.0)	<0.001*	1.70 (1.5; 2.12)	1.30 (1.0; 1.63)	−0.3 (−0.56; 0.0)	0.0069*	0.972/0.917*
Free testosterone, pg/mL	0.10 (0.05; 0.16)	0.06 (0.04;0.09)	−0.01(−0.07; -0.00)	<0.001*	0.10 (0.07; 0.14)	0.07 (0.04; 0.09)	−0.02 (−0.07; −0.03)	0.0046*	0.061/0.138*
SHBG, nmol/L	25 (12; 51)	63 (54; 65)	29 (3.0; 51.0)	0.0010§	51 (26; 62)	80 (65; 90)	28 (3.0; 45.0)	0.0001§	0.056/0.019§
FAI, %	5.29 (1.3; 8.8)	2.52 (2.41; 2.77)	−2.4 (−0.83; 4.46)	<0.001*	3.42 (3.13; 5.77)	1.63 (1.54; 1.81)	−1.4 (−2.3; −0.11)	0.008*	0.002/0.084*
Fasting glucose, mmol/L	5.1 (4.8; 5.3)	4.9 (4.7; 5.1)	−0.06 (−0.4; 0.1)	0.3977§	4.9 (4.8; 5.2)	5 (4.5; 5.1)	−0.05 (−0.2; −0.11)	0.5059§	0.408/0.416§
Insulin, μU/mL	15 (11.8; 16.2)	9.1 (7.9; 14.7)	−6 (−8.0; −2.1)	0.0056*	5.4 (5.1; 6.0)	5.6 (5.1; 6.0)	0 (−0.8; 0.0)	0.8785*	<0.001/<0.001*
HOMA-IR	3.3 (3.0; 6.0)	2.1 (1.6; 3.8)	−1 (−1.9; −0.2)	0.0027*	1.0 (0.8; 2.1)	1.0 (1.0; 1.6)	0 (−0.3; 0.0)	0.0754*	0.004/0.004*

^§Mann-Whitney U test.

*Wilcoxon’s t-criterion.

p³, differences between groups 1 (p¹) and 2 (p²) before/after.